Jim Cramer Says Biotech is The Hottest Group in The Market Right Now

CNBC's Jim Cramer pushed viewers distant from the accustomed semiconductor and hyperscaler chatter. Instead, helium highlighted a radical helium says has softly go the market's leader. "There is simply a determination successful biotech that we person not talked astir astatine each that is truly extraordinary, and peculiarly since the alteration astatine the caput of the FDA," Cramer said. He added that "if you look astatine that chart, this is the radical that's the hottest radical successful the market."

The information backs him up. The iShares Biotechnology ETF (NYSEARCA: IBB) is up 16.06% twelvemonth to day and 19.15% implicit the past month, versus 9.22% YTD for the S&P 500. Over the past year, IBB has returned 51.45%.

This is Why Deals are Coming

Cramer laid retired the classical biotech playbook.

"You person galore companies that get adjacent to, if not having information that confirms a cause successful a peculiar area. And much often than not, they don't privation to person to walk the wealth connected a income force... And they sell, right, usually astatine rather an inflated price." He pinned the caller frost connected regulators, noting that nether the anterior medication takeovers were sparse aft an Amgen woody "was astir blocked." With the FDA enactment change, Cramer said his sources expect deals to "be flooding the market." And that investors should beryllium agelong biotech, a telephone helium "has not said successful ages."

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Eli Lilly didn't marque the cut. Grab the names FREE today.

Lilly is the checkbook

The clearest grounds is Eli Lilly (NYSE: LLY), the $1.16 trillion pharma elephantine that has already announced 4 acquisitions successful Q1 2026. That includes Orna Therapeutics (cell therapies), Centessa Pharmaceuticals (sleep-wake disorders), Kelonia Therapeutics (in vivo CAR-T), and Ajax Therapeutics (myelofibrosis). That woody cadence is being funded by an obesity and diabetes franchise firing connected each cylinders. Mounjaro gross reached $8.66 cardinal (+125%). Zepbound deed $4.16 cardinal (+80%) successful Q1, helping Lilly present EPS of $8.55 connected $19.80 cardinal successful revenue, up 55.5% twelvemonth implicit year, per its SEC filing. Shares are up 13.34% YTD and 56.86% implicit the past year.